Original release date:
June 20, 2019
Access to this course expires on: April 3, 2022
at 11:59 PM Pacific Time
Hematopoietic neoplasms are highly heterogeneous, composed of numerous clinicopathologic subtypes and variants, and may present at many organ sites. The diagnostic evaluation of lymphomas and hematopoietic neoplasms presenting at nodal and extra-nodal sites requires careful integration of histologic, immunophenotypic, clinical and molecular features. Furthermore, rapid advances in the genetic/genomic understanding of these diseases pose a significant challenge to staying abreast of the diagnostic criteria, immunophenotypic and molecular prognostic/therapeutic markers that have clinical impact. This is underscored by diminishing sample sizes in biopsies of extra-nodal lesions and needle core biopsies of lymph nodes. In addition, the role of the pathologist as integrators of information is expanding rapidly.
This educational activity will highlight practical aspects representing important changes that impact the diagnostic approach to challenging extra-nodal hematopoietic neoplasms, cutaneous lymphomas, T-cell lymphomas and needle core biopsies from lymph nodes.
Practicing academic and community pathologists, and pathologists-in-training
Upon completion of this educational activity, learners will be able to:
- Develop diagnostic approaches to challenging extra-nodal hematopoietic neoplasms,
cutaneous lymphomas, T-cell lymphomas and needle core biopsies from lymph nodes
- Facilitate better use of immunohistochemical and molecular studies to identify clinically relevant
subtypes of cutaneous lymphomas and T-cell lymphomas
- Improve ability to distinguish the subtypes of T-cell lymphomas
- Refine skills to distinguish subtypes of hematopoietic neoplasms that present in extra-nodal sites
- Enhance capacity to evaluate lymphomas for clinically-relevant therapeutic targets
Continuing Medical Education and Continuing Certification
The United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The United States and Canadian Academy of Pathology designates this enduring material for a maximum of 12.25
AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
USCAP is approved by the American Board of Pathology (ABPath) to offer Self-Assessment credits (SAMs) and Lifelong Learning (Part II) credit for the purpose of meeting the ABPath requirements for Continuing Certification (CC). Registrants must take and pass the post-test in order to claim SAMs credit.
Physicians can earn a maximum of 12.25 SAM/Part II credit hours.
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to USCAP and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. USCAP has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The following faculty reported no relevant financial relationships: Megan Lim, MD, PhD; Joseph Khoury, MD; Alejandro Gru, MD; Nathanael Bailey, MD; Elaine Jaffe, MD
The following IM Coordinator who planned and reviewed content for this activity reported no relevant financial relationships: Megan Lim, MD, PhD
USCAP staff associated with the development of content for this activity reported no relevant financial relationships.
To earn CME and SAM credit, all learners must complete the evaluation. Your certificate will be available to view and print by
Not A Member? Click Here